| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1001772817 |
| P356 | DOI | 10.1038/NM.1908 |
| P2888 | exact match | https://scigraph.springernature.com/pub.10.1038/nm.1908 |
| P698 | PubMed publication ID | 19122658 |
| P50 | author | Jacek Jassem | Q19690551 |
| Véronique Becette | Q42698057 | ||
| Emmanuel Blot | Q125317233 | ||
| Richard Iggo | Q125317383 | ||
| P2093 | author name string | Hervé Bonnefoi | |
| David Cameron | |||
| Mario Campone | |||
| Mauro Delorenzi | |||
| Jonas Bergh | |||
| Pascale Anderle | |||
| Martine Piccart | |||
| Thierry Petit | |||
| Pratyaksha Wirapati | |||
| Frédéric Bibeau | |||
| Gaëtan Macgrogan | |||
| Jan Bogaerts | |||
| Etienne Brain | |||
| Michel Aguet | |||
| Sylvie André | |||
| Pierre Farmer | |||
| P2860 | cites work | The epithelial-mesenchymal transition generates cells with properties of stem cells | Q24650786 |
| Determination of stromal signatures in breast carcinoma | Q24798099 | ||
| Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications | Q27860709 | ||
| A gene-expression signature as a predictor of survival in breast cancer | Q27860945 | ||
| Molecular portraits of human breast tumours | Q28032461 | ||
| In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells | Q29616498 | ||
| Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy | Q29617584 | ||
| Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis | Q30004190 | ||
| A stromal gene signature associated with inflammatory breast cancer. | Q30838525 | ||
| The molecular portraits of breast tumors are conserved across microarray platforms | Q33241398 | ||
| Gene expression signatures of morphologically normal breast tissue identify basal-like tumors | Q33261032 | ||
| Stromal gene expression predicts clinical outcome in breast cancer | Q33330931 | ||
| Systemic endocrine instigation of indolent tumor growth requires osteopontin | Q33343851 | ||
| Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer | Q33989876 | ||
| Genomic signatures to guide the use of chemotherapeutics. | Q34576027 | ||
| Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial | Q34714877 | ||
| Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of breast cancer subtyping and prognosis signatures | Q36955113 | ||
| No evidence of clonal somatic genetic alterations in cancer-associated fibroblasts from human breast and ovarian carcinomas | Q37098932 | ||
| beta4 integrin-dependent formation of polarized three-dimensional architecture confers resistance to apoptosis in normal and malignant mammary epithelium | Q37460431 | ||
| Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines | Q41328166 | ||
| Identification of molecular apocrine breast tumours by microarray analysis. | Q42478400 | ||
| Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells | Q43727826 | ||
| Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer | Q44541885 | ||
| Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment | Q45099316 | ||
| Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. | Q46398274 | ||
| Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer | Q46502892 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. | Q51935846 | ||
| Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. | Q51943531 | ||
| Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18 | Q74715865 | ||
| Linking oncogenic pathways with therapeutic opportunities | Q80130796 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chemotherapy | Q974135 |
| P304 | page(s) | 68-74 | |
| P577 | publication date | 2009-01-04 | |
| P1433 | published in | Nature Medicine | Q1633234 |
| P1476 | title | A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer | |
| P478 | volume | 15 |
| Q51039907 | A 20-gene signature in predicting the chemoresistance of breast cancer to taxane-based chemotherapy. |
| Q38738541 | A COL11A1-correlated pan-cancer gene signature of activated fibroblasts for the prioritization of therapeutic targets |
| Q36714160 | A Composite Gene Expression Signature Optimizes Prediction of Colorectal Cancer Metastasis and Outcome. |
| Q58698491 | A Paradoxical Correlation of Cancer-Associated Fibroblasts With Survival Outcomes in B-Cell Lymphomas and Carcinomas |
| Q35640223 | A breast cancer meta-analysis of two expression measures of chromosomal instability reveals a relationship with younger age at diagnosis and high risk histopathological variables |
| Q35683578 | A clinically relevant gene signature in triple negative and basal-like breast cancer |
| Q37624417 | A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer |
| Q35106947 | A core invasiveness gene signature reflects epithelial-to-mesenchymal transition but not metastatic potential in breast cancer cell lines and tissue samples |
| Q37826352 | A digest on the role of the tumor microenvironment in gastrointestinal cancers |
| Q35206586 | A functional in vitro model of heterotypic interactions reveals a role for interferon-positive carcinoma associated fibroblasts in breast cancer. |
| Q57459920 | A genomic ruler to assess oncogenic transition between breast tumor and stroma |
| Q33914753 | A multifactorial 'Consensus Signature' by in silico analysis to predict response to neoadjuvant anthracycline-based chemotherapy in triple-negative breast cancer. |
| Q89529508 | ADAM12 is A Potential Therapeutic Target Regulated by Hypomethylation in Triple-Negative Breast Cancer |
| Q41548025 | ADAM12-L confers acquired 5-fluorouracil resistance in breast cancer cells |
| Q35155403 | ADAM12-L is a direct target of the miR-29 and miR-200 families in breast cancer |
| Q39929155 | Aiming at the target: improved adjuvant medical therapy |
| Q24644185 | Amplification of LAPTM4B and YWHAZ contributes to chemotherapy resistance and recurrence of breast cancer |
| Q36187733 | An "elite hacker": breast tumors exploit the normal microenvironment program to instruct their progression and biological diversity |
| Q27334982 | An unsupervised MVA method to compare specific regions in human breast tumor tissue samples using ToF-SIMS |
| Q38017302 | An update on chemotherapy and tumor gene expression profiles in breast cancer |
| Q83975441 | Analysis of stromal gene expression for the identification of prognostic and predictive molecular markers in cancer therapy |
| Q54560587 | Anthracyclines, HER2, and TOP2A: the verdict. |
| Q35760937 | Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells |
| Q39734181 | Assessment of an RNA interference screen-derived mitotic and ceramide pathway metagene as a predictor of response to neoadjuvant paclitaxel for primary triple-negative breast cancer: a retrospective analysis of five clinical trials |
| Q34701521 | Association between SPARC mRNA expression, prognosis and response to neoadjuvant chemotherapy in early breast cancer: a pooled in-silico analysis |
| Q37328400 | Associations Between Elastography Findings and Clinicopathological Factors in Breast Cancer. |
| Q34663710 | Biological characteristics and genetic heterogeneity between carcinoma-associated fibroblasts and their paired normal fibroblasts in human breast cancer |
| Q38052925 | Biomarkers in the diagnosis of primary and recurrent breast cancer |
| Q34611062 | Biomolecular events in cancer revealed by attractor metagenes |
| Q47143527 | Bone microenvironment has an influence on the histological response of osteosarcoma to chemotherapy: retrospective analysis and preclinical modeling |
| Q35370118 | Breast cancer - one term, many entities? |
| Q37803121 | Breast cancer assessment tools and optimizing adjuvant therapy. |
| Q38221967 | Breast cancer classification: linking molecular mechanisms to disease prognosis |
| Q37901429 | Breast cancer stem cells and their role in resistance to endocrine therapy |
| Q35571904 | Breast cancer stem cells, cytokine networks, and the tumor microenvironment |
| Q46323956 | Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. |
| Q33555526 | Breast tumour stroma is a prognostic indicator and target for therapy |
| Q37665460 | CEACAM1 controls the EMT switch in murine mammary carcinoma in vitro and in vivo |
| Q33880064 | Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models |
| Q37352596 | Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? |
| Q35523700 | Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells |
| Q91754848 | Cancer-associated fibroblasts-heroes or villains? |
| Q34948192 | Candidate markers that associate with chemotherapy resistance in breast cancer through the study on Taxotere-induced damage to tumor microenvironment and gene expression profiling of carcinoma-associated fibroblasts (CAFs). |
| Q34593813 | Candidate pathways linking inducible nitric oxide synthase to a basal-like transcription pattern and tumor progression in human breast cancer. |
| Q35947022 | Cellular senescence and cancer chemotherapy resistance |
| Q36544073 | Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer |
| Q35655229 | Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer microenvironment |
| Q39936131 | Characterization and functional role of the stroma compartment in prostate tumors |
| Q34533478 | Chimaerin suppresses Rac1 activation at the apical membrane to maintain the cyst structure |
| Q34417532 | Chromosome 17 centromere duplication and responsiveness to anthracycline-based neoadjuvant chemotherapy in breast cancer. |
| Q34339847 | Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization |
| Q92824108 | Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial |
| Q54856495 | Clinico-pathological and transcriptomic determinants of SLFN11 expression in invasive breast carcinoma. |
| Q92839621 | Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer |
| Q38955561 | Clonal variation in interferon response determines the outcome of oncolytic virotherapy in mouse CT26 colon carcinoma model. |
| Q42380391 | Combinatorial Microenvironments Impose a Continuum of Cellular Responses to a Single Pathway-Targeted Anti-cancer Compound |
| Q97538334 | Comprehensive characterization of claudin-low breast tumors reflects the impact of the cell-of-origin on cancer evolution |
| Q64922761 | Comprehensive functional profiling of long non-coding RNAs through a novel pan-cancer integration approach and modular analysis of their protein-coding gene association networks. |
| Q33974305 | Consistent metagenes from cancer expression profiles yield agent specific predictors of chemotherapy response |
| Q35733734 | Constitutive phosphorylated STAT3-associated gene signature is predictive for trastuzumab resistance in primary HER2-positive breast cancer |
| Q92043014 | Contribution of Epithelial Plasticity to Therapy Resistance |
| Q35037058 | Contribution of bone microenvironment to leukemogenesis and leukemia progression |
| Q34100400 | Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes |
| Q42374960 | Correlation of X-ray diffraction signatures of breast tissue and their histopathological classification. |
| Q38779433 | Creating chemotherapeutic-resistant breast cancer cell lines: advances and future perspectives |
| Q37968500 | Critical choices for modeling breast cancer in transgenic mouse models. |
| Q41694184 | Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis |
| Q34034112 | Cyclin D1, Id1 and EMT in breast cancer |
| Q34314896 | Defining new criteria for selection of cell-based intestinal models using publicly available databases. |
| Q39181819 | Dense breast tissue in postmenopausal women is associated with a pro-inflammatory microenvironment in vivo |
| Q34340016 | Development of a prognostic model for breast cancer survival in an open challenge environment. |
| Q39033034 | Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes. |
| Q41136230 | Disorganised stroma determined on pre-treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial |
| Q35187831 | Does shear wave ultrasound independently predict axillary lymph node metastasis in women with invasive breast cancer? |
| Q49936518 | Drug repurposing screening identifies bortezomib and panobinostat as drugs targeting cancer associated fibroblasts (CAFs) by synergistic induction of apoptosis. |
| Q36545168 | Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs |
| Q54380363 | E-Cadherin and EpCAM expression by NSCLC tumour cells associate with normal fibroblast activation through a pathway initiated by integrin αvβ6 and maintained through TGFβ signalling. |
| Q39233875 | EMT, CSCs, and drug resistance: the mechanistic link and clinical implications |
| Q53084133 | Early Evaluation of Relative Changes in Tumor Stiffness by Shear Wave Elastography Predicts the Response to Neoadjuvant Chemotherapy in Patients With Breast Cancer. |
| Q100490624 | Emerging role of tumor cell plasticity in modifying therapeutic response |
| Q38086421 | Emerging targeted agents in metastatic breast cancer |
| Q92263922 | Endothelial miR-30c suppresses tumor growth via inhibition of TGF-β-induced Serpine1 |
| Q93137076 | Engineering Multidimensional Evolutionary Forces to Combat Cancer |
| Q93225562 | Epithelial-Mesenchymal Transition in Cancer: A Historical Overview |
| Q39085731 | Epithelial-mesenchymal transition in tumor metastasis |
| Q34880376 | Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. |
| Q33584106 | Expression of Myxovirus Resistance A (MxA) Is Associated with Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancers |
| Q89761230 | Extracellular Matrix Features Discriminate Aggressive HER2-Positive Breast Cancer Patients Who Benefit from Trastuzumab Treatment |
| Q35023227 | F11R is a novel monocyte prognostic biomarker for malignant glioma |
| Q34653113 | FOXQ1, a novel target of the Wnt pathway and a new marker for activation of Wnt signaling in solid tumors |
| Q33964324 | Fibroblast heterogeneity in the cancer wound |
| Q35987339 | Fibroblast surface-associated FGF-2 promotes contact-dependent colorectal cancer cell migration and invasion through FGFR-SRC signaling and integrin αvβ5-mediated adhesion |
| Q35656269 | Fibroblasts Influence Survival and Therapeutic Response in a 3D Co-Culture Model |
| Q55324986 | Fibroblasts in the Tumor Microenvironment: Shield or Spear? |
| Q35920503 | Fibroblasts--a key host cell type in tumor initiation, progression, and metastasis |
| Q90138987 | Fibrosis and cancer: A strained relationship |
| Q46214350 | From transformation to metastasis: deconstructing the extracellular matrix in breast cancer |
| Q34704073 | GOBO: gene expression-based outcome for breast cancer online |
| Q37109711 | Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets |
| Q38836952 | Gene expression profile of normal and cancer-associated fibroblasts according to intratumoral inflammatory cells phenotype from breast cancer tissue |
| Q51905406 | Gene expression profile predicts outcome after anthracycline-based adjuvant chemotherapy in early breast cancer. |
| Q37528475 | Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival |
| Q37958156 | Gene expression profiling in breast cancer: classification, prognostication, and prediction |
| Q92331139 | Gene signature characteristic of elevated stromal infiltration and activation is associated with increased risk of hematogenous and lymphatic metastasis in serous ovarian cancer |
| Q36525765 | Gene signatures in breast cancer: current and future uses |
| Q35849104 | Gene-expression signature functional annotation of breast cancer tumours in function of age |
| Q96431681 | Gene-signature-derived IC50s/EC50s reflect the potency of causative upstream targets and downstream phenotypes |
| Q28079323 | Genetically engineered mouse models in oncology research and cancer medicine |
| Q64106252 | Genomic signature of parity in the breast of premenopausal women |
| Q37598468 | Glucocorticoid receptor signalling activates YAP in breast cancer |
| Q34019589 | HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data |
| Q37704659 | Hallmarks of cancer: interactions with the tumor stroma. |
| Q33753945 | Heterogeneity of gene expression in stromal fibroblasts of human breast carcinomas and normal breast |
| Q42370969 | High Intratumoral Stromal Content Defines Reactive Breast Cancer as a Low-risk Breast Cancer Subtype |
| Q33739228 | High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes |
| Q92354990 | High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation |
| Q37688210 | High expression of intratumoral stromal proteins is associated with chemotherapy resistance in breast cancer. |
| Q37601713 | High expression of stromal PDGFRβ is associated with reduced benefit of tamoxifen in breast cancer |
| Q34119025 | Homogeneous datasets of triple negative breast cancers enable the identification of novel prognostic and predictive signatures |
| Q34407226 | Human breast cancer associated fibroblasts exhibit subtype specific gene expression profiles |
| Q35530169 | Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells |
| Q36693275 | Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy |
| Q45339162 | Identification of a gene signature associated with radiotherapy and prognosis in gliomas |
| Q33911170 | Identification of prognostic molecular features in the reactive stroma of human breast and prostate cancer |
| Q35992815 | Identification of stromal ColXα1 and tumor-infiltrating lymphocytes as putative predictive markers of neoadjuvant therapy in estrogen receptor-positive/HER2-positive breast cancer |
| Q35860895 | Identification of tumor epithelium and stroma in tissue microarrays using texture analysis |
| Q38206386 | Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses |
| Q33919243 | Importance of pre-analytical steps for transcriptome and RT-qPCR analyses in the context of the phase II randomised multicentre trial REMAGUS02 of neoadjuvant chemotherapy in breast cancer patients |
| Q90043623 | In Vitro and Ex Vivo Models - The Tumor Microenvironment in a Flask |
| Q33761298 | In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome |
| Q26781263 | In vitro cancer cell-ECM interactions inform in vivo cancer treatment |
| Q33645935 | Increased entropy of signal transduction in the cancer metastasis phenotype |
| Q35225647 | Increased expression of chemerin in squamous esophageal cancer myofibroblasts and role in recruitment of mesenchymal stromal cells |
| Q37854731 | Influence of the tumor microenvironment on angiogenesis |
| Q53226384 | Inhibition of epithelial-to-mesenchimal transition: a novel tumor suppressor function of p53? |
| Q37181531 | Integrated genomic analysis of breast cancers |
| Q37968654 | Integrating breast cancer genetics into clinical practice. |
| Q35561695 | Integrating contextual miRNA and protein signatures for diagnostic and treatment decisions in cancer |
| Q38398206 | Interferons and the Immunogenic Effects of Cancer Therapy |
| Q29620149 | Intra-tumour heterogeneity: a looking glass for cancer? |
| Q40489826 | Intra-tumoural stromal morphometry predicts disease recurrence but not response to 5-fluorouracil - results from the QUASAR trial of colorectal cancer. |
| Q37815128 | Jekyll and Hyde: the role of the microenvironment on the progression of cancer |
| Q91902273 | Landscape of transcriptomic interactions between breast cancer and its microenvironment |
| Q90233649 | Latest Advances in Targeting the Tumor Microenvironment for Tumor Suppression |
| Q34429766 | Low ERK phosphorylation in cancer-associated fibroblasts is associated with tamoxifen resistance in pre-menopausal breast cancer |
| Q33708991 | MPA-induced gene expression and stromal and parenchymal gene expression profiles in luminal murine mammary carcinomas with different hormonal requirements. |
| Q57816590 | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
| Q90453024 | Macrophages confer resistance to PI3K inhibitor GDC-0941 in breast cancer through the activation of NF-κB signaling |
| Q37331580 | Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. |
| Q28084572 | Membrane-to-Nucleus Signals and Epigenetic Mechanisms for Myofibroblastic Activation and Desmoplastic Stroma: Potential Therapeutic Targets for Liver Metastasis? |
| Q89631282 | Mesenchymal Stem Cells in the Tumor Microenvironment |
| Q37565450 | Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. |
| Q39113929 | Mesenchymal stem cells: key players in cancer progression |
| Q33770298 | Mesenchymal/stromal gene expression signature relates to basal-like breast cancers, identifies bone metastasis and predicts resistance to therapies |
| Q37352137 | Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. |
| Q35558070 | Microarrays in the 2010s: the contribution of microarray-based gene expression profiling to breast cancer classification, prognostication and prediction |
| Q42932576 | Microenvironment-a role in tumour progression and prognosis |
| Q33654609 | Microenvironmental regulation of therapeutic response in cancer |
| Q35101607 | Mining the tissue-tissue gene co-expression network for tumor microenvironment study and biomarker prediction |
| Q36739364 | Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions |
| Q30493647 | Modulation of cellular migration and survival by c-Myc through the downregulation of urokinase (uPA) and uPA receptor |
| Q92538958 | Molecular apocrine tumours in EORTC 10994/BIG 1-00 phase III study: pathological response after neoadjuvant chemotherapy and clinical outcomes |
| Q37751530 | Molecular basis for therapy resistance |
| Q42147001 | Molecular characteristics of residual cancer and stromal cells after chemoradiotherapy for gastric cancer: report of four cases |
| Q26783806 | Molecular classification and prediction in gastric cancer |
| Q38184381 | Molecular tests as prognostic factors in breast cancer |
| Q33737136 | Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. |
| Q48277126 | Mutual dependence of the MRTF-SRF and YAP-TEAD pathways in cancer-associated fibroblasts is indirect and mediated by cytoskeletal dynamics |
| Q37510892 | Neoadjuvant chemotherapy for early breast cancer |
| Q36618752 | Neoplastic and stromal cells contribute to an extracellular matrix gene expression profile defining a breast cancer subtype likely to progress |
| Q26771894 | New Findings on Breast Cancer Stem Cells: A Review |
| Q37044600 | Noncanonical TGF-β signaling during mammary tumorigenesis |
| Q92891631 | Novel methodology to image stromal tissue and assess its morphological features with polarized light: towards a tumour microenvironment prognostic signature |
| Q39456875 | Nutrient Exploitation within the Tumor-Stroma Metabolic Crosstalk |
| Q42140314 | Of mice and men: a comparative study of cancer-associated fibroblasts in mammary carcinoma. |
| Q39011826 | One microenvironment does not fit all: heterogeneity beyond cancer cells |
| Q42762256 | Optimally discriminative subnetwork markers predict response to chemotherapy |
| Q41878315 | Origin and interpretation of cancer transcriptome profiling: the essential role of the stroma in determining prognosis and drug resistance |
| Q37444430 | Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. |
| Q36039273 | Oxidative stress promotes myofibroblast differentiation and tumour spreading |
| Q35955369 | PDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy |
| Q28732256 | Parallel evolution under chemotherapy pressure in 29 breast cancer cell lines results in dissimilar mechanisms of resistance |
| Q102141449 | Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07) |
| Q60310902 | Potential protective effect of ALDH-1 stromal expression against early recurrence of operable breast cancers |
| Q34786543 | Potential therapeutic effect of the secretome from human uterine cervical stem cells against both cancer and stromal cells compared with adipose tissue stem cells |
| Q43067630 | Potential utility of an expression array signature for predicting anthracycline responsiveness or resistance |
| Q57162797 | Pre-operative stromal stiffness measured by shear wave elastography is independently associated with breast cancer-specific survival |
| Q28539028 | Predicting response to preoperative chemotherapy agents by identifying drug action on modeled microRNA regulation networks |
| Q36117673 | Prediction and prognosis: impact of gene expression profiling in personalized treatment of breast cancer patients |
| Q47801747 | Prediction of pathological response to neoadjuvant treatment in rectal cancer with a two-protein immunohistochemical score derived from stromal gene-profiling. |
| Q86104177 | Presence of podoplanin-positive cancer-associated fibroblasts in surgically resected primary lung adenocarcinoma predicts a shorter progression-free survival period in patients with recurrences who received platinum-based chemotherapy |
| Q36791086 | Primary extraosseous Ewing sarcoma of the lung in children |
| Q39543888 | Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts |
| Q36957198 | Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance |
| Q41880628 | Prognostic and functional role of subtype-specific tumor-stroma interaction in breast cancer |
| Q39499250 | Prognostic significance of androgen receptor expression in invasive breast cancer: transcriptomic and protein expression analysis |
| Q37257191 | Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer |
| Q43475965 | Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854). |
| Q35180291 | Prognostic stromal gene signatures in breast cancer. |
| Q41535142 | Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. |
| Q36241768 | Proteomic characterization of microdissected breast tissue environment provides a protein-level overview of malignant transformation |
| Q24658369 | Quis custodiet ipsos custodies: who watches the watchmen? |
| Q38387030 | RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. |
| Q26863751 | Recent developments in myofibroblast biology: paradigms for connective tissue remodeling |
| Q36402018 | Release of TGFβig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression. |
| Q42223681 | Report on the first SLFN11 monothematic workshop: from function to role as a biomarker in cancer |
| Q37404590 | Resistance to endocrine therapy: are breast cancer stem cells the culprits? |
| Q36625697 | Role of the microenvironment in the pathogenesis and treatment of hepatocellular carcinoma |
| Q40007032 | SNRFCB: sub-network based random forest classifier for predicting chemotherapy benefit on survival for cancer treatment |
| Q38781193 | Shear-wave elastography in breast ultrasonography: the state of the art. |
| Q35558904 | Signaling pathways in breast cancer metastasis - novel insights from functional genomics |
| Q87852511 | Simultaneous analysis of the gene expression profiles of cancer and stromal cells in endometrial cancer |
| Q43562850 | Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes |
| Q59794209 | Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing |
| Q33684080 | Specific kinesin expression profiles associated with taxane resistance in basal-like breast cancer |
| Q37606432 | Src is activated by the nuclear receptor peroxisome proliferator-activated receptor β/δ in ultraviolet radiation-induced skin cancer |
| Q57160043 | Stress signaling in breast cancer cells induces matrix components that promote chemoresistant metastasis |
| Q33663923 | Stroma in breast development and disease. |
| Q91809653 | Stromal Cell Signature Associated with Response to Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer |
| Q34810329 | Stromal LRP1 in lung adenocarcinoma predicts clinical outcome |
| Q39274735 | Stromal adipocyte enhancer-binding protein (AEBP1) promotes mammary epithelial cell hyperplasia via proinflammatory and hedgehog signaling |
| Q38017601 | Stromal biomarkers in breast cancer development and progression |
| Q35609967 | Stromal cells in tumor microenvironment and breast cancer |
| Q28066162 | Stromal characteristics may hold the key to mammographic density: the evidence to date |
| Q38906913 | Stromal contribution to the colorectal cancer transcriptome. |
| Q36640187 | Stromal expression of matrix metalloproteinase 2 in cancer-associated fibroblasts is strongly related to human epidermal growth factor receptor 2 status in invasive breast carcinoma |
| Q34647811 | Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. |
| Q36040493 | Stromal genes add prognostic information to proliferation and histoclinical markers: a basis for the next generation of breast cancer gene signatures |
| Q53275913 | Stromal markers AKR1C1 and AKR1C2 are prognostic factors in primary human breast cancer. |
| Q36372792 | Suboptimal cytoreduction in ovarian carcinoma is associated with molecular pathways characteristic of increased stromal activation |
| Q37040574 | TGF-β stimulates Pyk2 expression as part of an epithelial-mesenchymal transition program required for metastatic outgrowth of breast cancer |
| Q64239576 | TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers |
| Q39336778 | TOP2A protein by quantitative immunofluorescence as a predictor of response to epirubicin in the neoadjuvant treatment of breast cancer |
| Q34523263 | Tackling the cancer stem cells - what challenges do they pose? |
| Q58619072 | Targeting Metabolomics in Breast Cancer |
| Q35723957 | Targeting of distinct signaling cascades and cancer-associated fibroblasts define the efficacy of Sorafenib against prostate cancer cells |
| Q64119664 | Targeting stem cells in the realm of drug-resistant breast cancer |
| Q61135683 | Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer |
| Q92349505 | Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy |
| Q36150219 | Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment |
| Q37952796 | Targeting the tumor microenvironment by immunotherapy: part 2. |
| Q43149410 | Ten-gene biomarker panel: a new hope for ovarian cancer? |
| Q35577928 | Tenascin C in metastasis: A view from the invasive front |
| Q45068538 | The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis |
| Q38679301 | The Microenvironment of Lung Cancer and Therapeutic Implications |
| Q57585219 | The Role of Tumor Microenvironment in Chemoresistance: 3D Extracellular Matrices as Accomplices |
| Q38828825 | The biology and function of fibroblasts in cancer |
| Q38037329 | The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance |
| Q38644660 | The extracellular matrix in breast cancer predicts prognosis through composition, splicing, and crosslinking. |
| Q26851314 | The microenvironment in breast cancer progression: biology and implications for treatment |
| Q57287686 | The prognostic value of tumour-stroma ratio in primary breast cancer with special attention to triple-negative tumours: a review |
| Q38483125 | The relevance of EMT in breast cancer metastasis: Correlation or causality? |
| Q45202800 | The role of biological markers of epithelial to mesenchymal transition in oesophageal adenocarcinoma, an immunohistochemical study |
| Q56762925 | The sbv IMPROVER Systems Toxicology Computational Challenge: Identification of Human and Species-Independent Blood Response Markers as Predictors of Smoking Exposure and Cessation Status |
| Q49319044 | Three-dimensional tumor model mimics stromal - breast cancer cells signaling. |
| Q34433737 | Topo2α protein expression predicts response to anthracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer |
| Q36695058 | Transcription factor networks in invasion-promoting breast carcinoma-associated fibroblasts |
| Q34552025 | Transcriptional shift identifies a set of genes driving breast cancer chemoresistance |
| Q34897615 | Transfer of clinically relevant gene expression signatures in breast cancer: from Affymetrix microarray to Illumina RNA-Sequencing technology |
| Q51776900 | Transformed epithelial cells and fibroblasts/myofibroblasts interaction in breast tumor: a mathematical model and experiments. |
| Q38092582 | Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies |
| Q37984168 | Tumor microenvironment and breast cancer progression: a complex scenario |
| Q26866052 | Tumor microenvironment and the pathologist: looking at what we just see |
| Q34343963 | Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer. |
| Q26785362 | Tumor-extracellular matrix interactions: Identification of tools associated with breast cancer progression |
| Q37507440 | Tumour-site-dependent expression profile of angiogenic factors in tumour-associated stroma of primary colorectal cancer and metastases. |
| Q27304708 | Understanding the impact of 2D and 3D fibroblast cultures on in vitro breast cancer models |
| Q86652377 | Using Frequent Co-expression Network to Identify Gene Clusters for Breast Cancer Prognosis |
| Q37812009 | Using gene expression profiling to predict response and prognosis in gastrointestinal cancers-the promise and the perils |
| Q37190437 | Whole transcriptome profiling of patient-derived xenograft models as a tool to identify both tumor and stromal specific biomarkers |
| Q29614274 | Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progression |
| Q27023385 | Why the stroma matters in breast cancer: insights into breast cancer patient outcomes through the examination of stromal biomarkers |
| Q33739204 | Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? |
| Q34140068 | p-Medicine: From data sharing and integration via VPH models to personalized medicine |
| Q43006079 | p27(Kip1) enforces maintenance of quiescence in the mammalian ear and the pituitary gland |
Search more.